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Reply to “Inclusion 
of Lymphangitis as a 
Descriptor in the New 
TNM Staging of Lung 
Cancer: Filling Up the 
Blank Spaces”
To the Editor:
We were excited to read the recent 
article containing the proposals related 
to T descriptors for the 8th edition of 
TNM staging of lung cancer.1 The pre-
vious International Association for the 
Study of Lung Cancer (IASLC) staging 
project that led to the implementation 
of the 7th edition has had phenomenal 
implications for clinical practice, and the 
same is likely for the 8th edition as well.
Since its ﬁrst description approxi-
mately 200 years ago, lymphangitis car-
cinomatosis has been realized as a marker 
of disseminated disease and thus of poor 
survival.2 The spread of tumor cells to 
the pulmonary lymphatic system results 
in thickening of the bronchovascular 
bundles and septa. The interstitial thick-
ening is also contributed by desmoplas-
tic reaction because of proliferation of 
neoplastic cells and lymphatic dilation by 
edema fluid or tumor secretions. Spread 
of the neoplasm outside the interstitium 
and lymphatic spaces into the adjacent 
parenchyma results in a nodular pattern.3
The radiological extent of distri-
bution of nodules (conﬁned to primary 
tumor lobe [categorized as T3], present 
in other ipsilateral lobes [categorized 
as T4], and present in the contralat-
eral lung [categorized as M1a]) has 
shown to correlate with overall sur-
vival.4 Categorization of nodules was 
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one of the prominent changes between 
the 6th and 7th TNM editions because 
the IASLC staging project had shown 
that presence of nodules in the primary 
tumor lobe and in other nonprimary 
ipsilateral lobes had survival similar 
to other T3 and T4 descriptors, respec-
tively, leading these to be downstaged 
from T4 and M1 in the 6th edition to T3 
and T4, respectively, in the 7th edition.
We understand that the extent of 
lymphangitis was thought to be of prog-
nostic signiﬁcance, as it was listed as an 
optional descriptor (cLy) in the 7th TNM 
with a grading from 0 to 4 (in a way some-
what analogous to presence of nodules).5
The proposed categorization was 
as follows:
cLy0:  no radiological evidence of 
lymphangitis
cLy1:  lymphangitis conﬁned to the area 
around the primary tumor
cLy2:  lymphangitis at a distance from 
the primary tumor but conﬁned 
to the lobe of the primary
cLy3:  lymphangitis in other ipsilateral 
lobes
cLy4:  lymphangitis affecting the 
 contralateral lung
Clinical features and radiological 
appearance of lymphangitis have been 
well characterized in general. However, 
we could not ﬁnd mention of prognostic 
implications of lymphangitis carcino-
matosis in the recent article containing 
proposals for the 8th edition. We are not 
aware whether this is planned to be incor-
porated in the proposals for M descrip-
tors. Nonetheless, this is a radiological 
ﬁnding that we encounter quite often in 
clinical practice and is something that 
needs to be addressed. It would also be 
interesting to note whether survival data 
based on above described cLy categori-
zation are comparable with that based 
on categorization of nodules.
We once again wish to congratu-
late the IASLC for undertaking the cur-
rent staging project and sincerely hope 
that unclassiﬁed descriptors such as 
lymphangitis carcinomatosis and oth-
ers ﬁnd mention in subsequent TNM 
editions backed by robust data analysis 
as has been the case for other T and M 
descriptors.
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In Response:
The Letter to the Editor by Singh et 
al.1 called our attention to the fact that 
lymphangitic carcinomatosis had not 
been mentioned in the recently pub-
lished article on the revised primary 
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